Clincosm LogoSign in Get a demo

Pneumoserocov: COVID 19 Serology in Pulmonologists

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Completed
CT.gov ID
NCT04422574
Collaborator
(none)
97
Enrollment
1
Location
29
Actual Duration (Days)
101.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Respiratory physicians are highly exposed workers to Covid-19 as they perform spirometry, endoscopy, and manage Covid-19 in first line for most of them. Moreover, none reported to have apply increased levels of protection for performing these acts in the most active period of viral circulation, until the lockdown. Whether they were most frequently immunized against SARS-CoV-2 at the end of the first wave than the general population is of utmost importance individually but also worldwide

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    97 participants
    Observational Model:
    Ecologic or Community
    Time Perspective:
    Cross-Sectional
    Official Title:
    COVID 19 Serology in Pulmonologists : Pneumo Sero Cov
    Actual Study Start Date :
    May 1, 2020
    Actual Primary Completion Date :
    May 1, 2020
    Actual Study Completion Date :
    May 30, 2020

    Outcome Measures

    Primary Outcome Measures

    1. covid 19 serology [1 day]

      covid 19 serology with cross sectional

    2. risk factors for positive serology testing [1 day]

      risk factors for positive serology testing with cross sectional

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Pulmonologists of Languedoc Roussillon

    • Actively working

    • Registered

    Exclusion Criteria:
    • refusal to participate

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uh Montpellier Montpellier France 34295

    Sponsors and Collaborators

    • University Hospital, Montpellier

    Investigators

    • Study Director: Arnaud Bourdin, MD PhD, University Hospital, Montpellier

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Montpellier
    ClinicalTrials.gov Identifier:
    NCT04422574
    Other Study ID Numbers:
    • RECHMPL20_0343
    First Posted:
    Jun 9, 2020
    Last Update Posted:
    Jun 9, 2020
    Last Verified:
    Jun 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Montpellier
    Covid 19
    serology
    Additional relevant MeSH terms:
    COVID-19

    Study Results

    No Results Posted as of Jun 9, 2020